The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Martina Bocchetta, Samantha Galluzzi, Patrick Gavin Kehoe, Eduardo Aguera, Roberto Bernabei, Roger Bullock, Mathieu Ceccaldi, Jean François Dartigues, Alexandre de Mendonça, Mira Didic, Maria Eriksdotter, Olivier Félician, Lutz Frölich, Hermann Josef Gertz, Merja Hallikainen, Steen G. Hasselbalch, Lucrezia Hausner, Isabell Heuser, Frank Jessen, Roy W. JonesAlexander Kurz, Brian Lawlor, Alberto Lleo, Pablo Martinez-Lage, Patrizia Mecocci, Shima Mehrabian, Andreas Monsch, Flavio Nobili, Agneta Nordberg, Marcel Olde Rikkert, Jean Marc Orgogozo, Florence Pasquier, Oliver Peters, Eric Salmon, Carmen Sánchez-Castellano, Isabel Santana, Marie Sarazin, Latchezar Traykov, Magda Tsolaki, Pieter Jelle Visser, Åsa K. Wallin, Gordon Wilcock, David Wilkinson, Henrike Wolf, Görsev Yener, Dina Zekry, Giovanni B. Frisoni*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

62 Citations (Scopus)


We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Aβ42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.

Original languageEnglish
Pages (from-to)195–206e1
JournalAlzheimer's and Dementia
Issue number2
Publication statusPublished - 20 Aug 2014


  • Alzheimer's disease
  • Biomarkers
  • Diagnosis
  • Mild cognitive impairment


Dive into the research topics of 'The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey'. Together they form a unique fingerprint.

Cite this